SCHEMBL18259367

SCHEMBL18259367

CCOC(=O)CCCC[C@@H]1CN(C(=O)OC(C)(C)C)CCO1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
USP2 O75604 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 2/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 4/20 0.40
RECQL P46063 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GLA P06280 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALOX15 P16050 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
PDK1 Q15118 3/20 0.36
ENPP2 Q13822 2/20 0.35
EPHA2 P29317 1/20 0.35
NR1H2 P55055 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18259368 1.00 RAB9A (0.43) RAB9AL3MBTL1USP2SMN1; SMN2TSHR
SCHEMBL29318675 0.97 RAB9A (0.44) RAB9AL3MBTL1USP2SMN1; SMN2TSHR
SCHEMBL18259310 0.92 USP2 (0.43) RAB9AL3MBTL1USP2SMN1; SMN2TSHR
SCHEMBL18259311 0.92 USP2 (0.43) RAB9AL3MBTL1USP2SMN1; SMN2TSHR
SCHEMBL18259631 0.92 USP2 (0.43) RAB9AL3MBTL1USP2SMN1; SMN2TSHR
SCHEMBL18259580 0.86 USP2 (0.44) USP2SMN1; SMN2ALDH1A1RECQLKDM4E
SCHEMBL18259581 0.86 USP2 (0.44) USP2SMN1; SMN2ALDH1A1RECQLKDM4E
SCHEMBL28581088 0.86 USP2 (0.47) RAB9AL3MBTL1USP2SMN1; SMN2TSHR
SCHEMBL18689545 0.83 USP2 (0.47) USP2SMN1; SMN2ALDH1A1RECQLKDM4E
SCHEMBL20913885 0.83 USP2 (0.47) USP2SMN1; SMN2ALDH1A1RECQLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3122747-B1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS NORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD (CN) 2020-05-20 EP disclosed
US-9771358-B2 Dihydropyrimidine compounds and their application in pharmaceuticals SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-09-26 US disclosed
US-20160347746-A1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160347746-A1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS DPYD, SLC10A1, HPRT1 RAB9A 2705/4885L3MBTL1 4328/4885USP2 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.